Superluminal Medicines focuses on GPCRs, a family of membrane proteins that are involved in a vast range of physiological processes and are the target of a large share of approved drugs. Despite their importance, GPCRs are notoriously difficult to drug because they are highly dynamic, shifting between many three-dimensional conformations. Superluminal's platform combines generative biology, computational chemistry, and machine learning to model these conformational states and rapidly design small molecules that engage the right target in the right shape.
The company describes its approach as drugging 'protein conformations in a flash,' compressing a discovery process that traditionally takes years into a far faster, AI-accelerated workflow. By generating and prioritizing drug candidates computationally before extensive lab work, Superluminal aims to expand the universe of GPCR targets that can be addressed with precision small-molecule medicines, opening up new treatment opportunities across cardiometabolic disease, obesity, and beyond.
Superluminal's scientific approach has attracted significant industry validation. In August 2025, the company signed a drug discovery collaboration with Eli Lilly worth up to roughly $1.3 billion in potential milestones, focused on cardiometabolic and obesity drug targets, an endorsement of both its platform and the strategic relevance of GPCRs in the metabolic disease arena that has reshaped the pharmaceutical industry.
In September 2024, Superluminal closed a $120 million Series A led by RA Capital Management, with participation from Insight Partners, NVIDIA's venture arm NVentures, Catalio Capital Management, Gaingels, and Eli Lilly. The funding advances Superluminal's lead program toward clinical development and expands its portfolio of small-molecule discovery programs against high-value GPCR targets.
With a differentiated focus on a high-value but hard-to-drug target class, a marquee pharma partnership, and strong investor backing including NVIDIA, Superluminal Medicines is positioned as a notable player in the AI-driven drug discovery landscape.